Description

Medicenna Therapeutics Corp. is an immunotherapy company dedicated to discovering and commercializing innovative Superkines and "empowered Superkines" for the treatment of various cancers and other ailments. The company's primary therapeutic candidate, MDNA55 (an interleukin-4 (IL-4) EC), has successfully completed a Phase IIb clinical trial for recurrent glioblastoma. This product is also in earlier preclinical and clinical development stages for other brain and non-brain tumors. Medicenna's pipeline also features several other promising compounds: MDNA11: An enhanced version of IL-2, engineered to activate and proliferate the immune cells essential for fighting cancer. MDNA209: An IL-2 antagonist aimed at treating autoimmune conditions such as multiple sclerosis and graft-versus-host disease. MDNA413: A dual IL-4/IL-13 antagonist being developed for cancer immunotherapies. MDNA132: An IL-13 Superkine currently in development for solid tumors. Additionally, the company utilizes its proprietary BiSKITs platform, an advanced technology designed to create custom Superkines by fusing them with other proteins, antibodies, cytokines, or Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.